<DOC>
	<DOCNO>NCT02464319</DOCNO>
	<brief_summary>Primary Sjögren 's Syndrome ( pSS ) autoimmune disorder characterize keratoconjunctivitis sicca xerostomia . In addition , various extraglandular manifestation may develop . Several immunomodulating agent attempt treatment pSS without achieve satisfactory result . Currently , approve systemic treatment pSS . Dysfunction regulatory T ( Treg ) cell detect diverse autoimmune disease , promote interleukin-2 ( IL-2 ) . The investigator hypothesize low-dose IL-2 could novel therapy active pSS patient . This clinical study test efficacy safety low dose IL-2 treatment pSS . The investigator perform single-centre , double-blind pilot trial hrIL-2 pSS . The investigator evaluate effectiveness safeness low-dose hrIL-2 primary Sjögren 's Syndrome randomize control study ( hrIL-2 ( N = 30 ) versus placebo group ( N = 30 ) ) .</brief_summary>
	<brief_title>A Phase II Study With Low-dose Recombinant Human IL-2 Treatment Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>Each pSS patient ( n=60 ) Scores &gt; =6 ESSDAI receive low-dose IL-2 placebo ( active group : placebo group =1:1 , 1 million unit every day subcutaneously ( HrIL-2 1X 106 , ip , Qod ) period 14 day . After 14-day rest , another cycle start ) 3 cycle . The end point safety , clinical immunologic response .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosis primary Sjögren´s Syndrome ESSDAI score ≥ 6 Liver value 1,5 ULN Stable low dose systemic use Glucocorticoids（ &lt; =7.5mg） last 4 week begin Study medication Secondary Sjögren 's Syndrome Pretreatment Cyclosporine A Receiving cyclosphosphamide , corticosteroid bolus dose 1 mg/kg , rituximab , belimumab , immunosuppressives Infection Neoplasia Relevant cardiac , pulmonary , neurologic psychiatric disease LifeVaccination within 4 week begin study medication Pregnant breastfeeding Weight 45kg 80kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>